Merit Medical Systems: The MedTech Compounder's Operational Awakening - $MMSI

Merit Medical built a $1.5 billion business on the unglamorous, indispensable hardware that powers everyday catheterization labs—from inflation syringes to specialized access sheaths. Yet decades of relentless, founder-led expansion through serial acquisitions eventually outpaced execution, triggering a sharp 2019 profit collapse that invited activist intervention. The resulting six-year operational overhaul engineered a dramatic margin expansion, stripping out excess costs and streamlining global manufacturing. Now, with its founder stepping down after nearly four decades, Merit faces its defining test under new leadership: proving whether its disciplined operating system can successfully shift into higher-margin therapeutic devices, or if its celebrated stock re-rating was merely a finite operational cleanup.---Subscribe to our newsletter on LinkedIn https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7408775804387491842Follow us on X @emportop---Transcript - https://empor.top/us/MMSII. Introduction & Episode RoadmapII. The Genesis: Fred Lampropoulos & The Cath-Lab Revolution (1987–2000)III. The Growth Engine & The Dark Side of Serial M&A (2001–2019)IV. The Starboard Activist Wake-Up Call & "Foundations for Growth" (2020–2023)V. Inside the Business Today: Segment Economics & Core Product MoatsVI. Capital Allocation 2.0, M&A Benchmarking & The Growth Pipeline (2023–2026+)VII. Porter's 5 Forces & Hamilton Helmer's 7 Powers AnalysisVIII. Management Credibility, Governance & Skeptical Investor Stress TestIX. Key Investment Spine, KPIs & Bear vs. Bull CaseX. Strategic Playbook & Investing LessonsReferences